Background: Pityriasis alba is a common cutaneous disorder usually asymptomatic, hypopigmented macules with or without mild scaling are its presenting lesions. Its etiology and pathogenesis are still poorly understood. Methodology:A descriptive cross-sectional study covered all patients with Pityriasis Alba attended the dermatology department. Results:A total of 86 patients with pityriasis alba, the age range was (2-20) years with a mean age of (8.9) years. Males were 53(61.6%) patients; females were 33(38.4%) patients. The frequency of patients started to decrease with an increase in age. Sunlight was incriminated as an aggravating factor in 32.55% (28 out of 86) patients, soap in 32.55% (28 out of 86) patients, and wind in 10.46% (9 out of 86) patients. Lesions were multiple in 91.8%, face involved in 78 patients (90.7%). History of recurrent illnesswas 21(24.4%), while those with no history of recurrence were 65 patients (75,6%). Lesions were characterized by erythema in 36.04%of patients,scaling in 76.74% of patients,hypopigmentation in 63.95% of patients, itching in 32.55% of patients, and burning sensation in 6.97%. Conclusion: Pityriasis Alba is a common disease usually in young, sunlight is of aggravating factor. Lesions are hypopigmented scaly mostly multiple.

Background: Psoriasis is a chronic inflammatory skin disease with an incompletely understood pathogenesis, partly an immune dysfunction. Immunomodulatory agents like biologics drugs are one of the systemic treatments being used. As a side effect, they can cause a form of hepatitis manifested by elevations of the blood liver enzymes. Methodology: A cross-section study of a total of fifty patients with severe chronic plaque psoriasis were treated with the biologic anti-TNF inhibitor agent, Etanercept, and followed up for twenty four months by regular blood liver enzymes estimations Results:Fourteen patients (28%) showed increased enzymes levels, of them five patients (10%) showed elevated alanine aminotransferase and/ or aspartate aminotransferase levels, six patients (12%) showed elevated alkaline phosphatase, and three patients (6%) showed elevated levels of the three enzymes at the same time. It was reported that almost all of them showed an acceptable amount of elevations which were less than two folds of the upper normal level and only two patients (4%) exceeded two folds of the upper normal level. Conclusion: The overall frequency of elevations in blood liver enzymes in our patients was 14 (28%) collectively.The range was from 6-12% according to the type of the enzyme. The onset of blood liver enzyme elevations was from 3 to 24 months after starting the medication.

No abstract